Evaluating the Efficacy of Pediatric Lipid Screening Alerts
Evaluating the Efficacy of Different Electronic Medical Record Alerts to Increase Pediatric Lipid Screening Across a Large Integrated Health System
1 other identifier
interventional
13,340
1 country
1
Brief Summary
The purpose of the study is to evaluate prospectively the impact of different system alerts on the prescription of lipid panels to pediatric Geisinger patients (9-11 years old), as per the now-universal guidelines. This will help quantify the relative effectiveness of different alerts and combinations of alerts on provider prescribing behavior and patient uptake of screening.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Oct 2019
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 3, 2019
CompletedFirst Posted
Study publicly available on registry
October 8, 2019
CompletedStudy Start
First participant enrolled
October 10, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 11, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
October 11, 2020
CompletedResults Posted
Study results publicly available
January 14, 2022
CompletedNovember 7, 2023
October 1, 2023
1 year
October 3, 2019
October 12, 2021
October 19, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Lipid Panel Order
Provider ordered a lipid panel to an eligible patient during the patient's first visit within the study period (binary variable).
1 day
Lipid Panel Screening
Patient completed a lipid panel screening within seven days of the patient's first visit (binary variable). This screening is not linked to any order made at the patient's first visit (i.e., Outcome Measure 1).
1 week
Study Arms (4)
Passive Control
NO INTERVENTIONWill consist of no alerts and will serve to examine lipid panel screening rates given the current standard of care. After 6 months, providers in this (and other conditions) will receive the alert(s) with the best demonstrated success in increasing screening rates.
Best Practice Alert (BPA-only)
EXPERIMENTALWill consist of a BPA that fires for providers during a visit with an eligible 9-11 year-old patient. This is an active opt-in alert wherein the provider must respond, either confirming the prescription of a lipid panel or opting out with an acknowledgment/reason for declining the test. The BPA will include a recommendation to administer the screen in combination with existing scheduled bloodwork.
Health Maintenance Topic (HMT-only)
EXPERIMENTALWill consist of an HMT in Epic that is present for providers at their visit with an eligible patient. The HMT will be highlighted for enhanced visibility, until or unless action is taken.
BPA+HMT
EXPERIMENTALWill consist of both the BPA and HMT presented simultaneously in Epic.
Interventions
An Epic screen pops up for a provider during an eligible 9-11 year-old patient's visit. A prompt requires that the provider respond, either confirming the prescription of a lipid panel or opting out with an acknowledgment/reason for declining the test.
An Epic health maintenance topic appears for a provider during an eligible 9-11 year-old patient's visit. The HMT will be highlighted for enhanced visibility, until or unless action is taken.
Eligibility Criteria
You may qualify if:
- male or female patients between the ages of 9 - 11
- seen within a primary care, cardiology, endocrinology, urgent care (CareWorks), or nutrition clinic at Geisinger
You may not qualify if:
- patients who have completed a lipid screen in the EMR
- patients who were determined to have familial hypercholesterolemia based on prior screening
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Geisinger Cliniclead
Study Sites (1)
Geisinger Health System
Danville, Pennsylvania, 17822, United States
Related Publications (1)
Goren A, Santos HC, Davis TW, Lowe RB, Monfette M, Meyer MN, Chabris CF. Comparison of Clinical Decision Support Tools to Improve Pediatric Lipid Screening. J Pediatr. 2024 Jun;269:113973. doi: 10.1016/j.jpeds.2024.113973. Epub 2024 Feb 22.
PMID: 38401785DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Limitations and Caveats
The description of the outcome measures was revised to be more accurate. The analysis plan was also modified from the plan outlined in the study description to include corrections for multiple comparisons (i.e., Tukey correction). Due to limited data access, only information about the orders and completions were given to the researchers. As a result, demographic data and data on adverse effects were not gathered.
Results Point of Contact
- Title
- Amir Goren, PhD
- Organization
- Geisinger Clinic
Study Officials
- PRINCIPAL INVESTIGATOR
Amir Goren, PhD
Geisinger Clinic
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, CARE PROVIDER
- Purpose
- SCREENING
- Intervention Model
- FACTORIAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Program Director, Behavioral Insights Team
Study Record Dates
First Submitted
October 3, 2019
First Posted
October 8, 2019
Study Start
October 10, 2019
Primary Completion
October 11, 2020
Study Completion
October 11, 2020
Last Updated
November 7, 2023
Results First Posted
January 14, 2022
Record last verified: 2023-10
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL
- Time Frame
- The data will become available after publication of study results in a scientific journal and will be available as long as the Open Science Framework hosts the data.
- Access Criteria
- The data on the Open Science Framework will be open to anyone requesting that information.
Data with no personally identifiable information will be made available to other researchers on the Open Science Framework for transparency. This will include the essential data and code needed to replicate the analysis that yielded reported findings.